SGLT2 independent effects of the SGLT2 inhibitor empagliflozin: Focus on the heart

Research output: PhD ThesisPhd-Thesis - Research and graduation internal

Abstract

This thesis explores how sodium glucose cotransporter 2 inhibitors (SGLT2i), particularly empagliflozin (EMPA), reduce cardiovascular risk by investigating their effects on cardiac infarction, hypertrophy, and heart failure (HF). SGLT2i demonstrate significant cardiovascular benefits across diabetic and non-diabetic populations, possibly through off-target effects. The study has
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
  • University of Amsterdam
Supervisors/Advisors
  • Hollmann, Markus, Supervisor
  • Coronel, Ruben, Supervisor
  • Zuurbier, Coert, Co-supervisor
  • Hauck, Nina, Co-supervisor
  • Hauck-Weber, N.C., Co-supervisor, External person
Award date17 Jun 2024
Print ISBNs9789493330924
Publication statusPublished - 2024

Cite this